Close Menu

Abbott

Abbott CEO Miles White said that while Alere is a bit of a fixer upper, he is pleased to have a resolution to issues surrounding the proposed acquisition. 

The firms also dropped their lawsuits against each other, and said they expect to complete the merger by the end of the third quarter.

The New York Stock Exchange gave Alere an additional six months to file its 2016 annual report, but it also said it could commence delisting proceedings at any time.  

Researchers and companies move to develop blood-based tests for concussion, according to Scientific American.

The firm said that its test is the first on the market to detect RSV infection at the point of care in 13 minutes or less.

The firm wants to develop a test that can provide objective, reliable, and rapid information so that clinicians can make critical decisions in circumstances of high uncertainty.

The FDA granted Abbott Emergency Use Authorization for the assay in serum, plasma, and urine in November. 

Companies with diverse infectious disease diagnostic technology offerings said that molecular methods are complementary to, not competitive with traditional diagnostics.

Abbott's commitment to closing the deal is still uncertain, but Alere's CEO said the regulatory clearance marks a "significant milestone." 

Separately, Alere said today that the European Commission has granted clearance for its acquistion by Abbott.

Pages

A new report offers ways for small, society publishers to transition to Plan S standards, ScienceInsider says.

A gas explosion sparked a fire at a Russian laboratory that stores dangerous pathogens, the Guardian reports.

Researchers turn to protein analysis to examine an ancient rhino sample, Smithsonian.com reports.

In PNAS this week: C2CD4A gene involved in insulin secretion, chromosome rearrangements in recurring S. aureus infections, and more.